GENEVA (AP) – Swiss pharmaceutical company Novartis AG posted a 3 percent rise in second-quarter profits Thursday, reflecting what it described as solid growth and an increased focus on core products.
Profits during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013, helped by “strong innovation momentum” and rising sales in some of its household brands, the Basel-based company reported.
Earlier this year, the company launched a major overhaul of its business with a series of multibillion-dollar deals with Britain’s GlaxoSmithKline PLC and the U.S.’s Eli Lilly & Co., a reflection of the restructuring that’s occurring in the fast-changing industry.
Novartis confirmed its outlook for 2014 is for mid-to-high single-digit sales growth, partly due to its confidence from progress and approvals for cancer and heart drugs that are in development.
CEO Joseph Jimenez told reporters the company delivered a solid quarter and is benefiting from “a sweeping transformation” of its commercial portfolio.
